Dr. Daniel Griffin: The US Is Paying $134 Million to Learn What Vaccines Already Knew — BigGo Finance

When Prevention Was the Product

The most expensive public-health intervention in America right now is not a new drug or a surgical procedure. It is an outbreak of a disease that should not exist. The United States has recorded 2,813 measles cases with five deaths — the first fatalities under the current HHS secretary, and the first in Pennsylvania in 35 years. According to a study in the journal Vaccine, the average cost of responding to a single measles case is $43,230. The bill for the current outbreak, still climbing as children return to crowded classrooms, is estimated at $134 million.

Dr. Daniel Griffin, an infectious disease specialist, has a blunt framing for this arithmetic. Speaking on This Week in Virology, he noted: “It’s a lot cheaper to get vaccinated. And it sure is kindler and the safer choice for our children.”

The math is not subtle. The measles vaccine costs roughly $73 per dose. The public-health response to one measles case — contact tracing, quarantine enforcement, laboratory testing, and emergency vaccination campaigns — costs nearly 600 times that amount. And the cost measured in morbidity is worse. As host Vincent Rakinello put it, for every five children infected, one ends up in the hospital “struggling to breathe, requiring supplemental oxygen, maybe even ending up in the ICU.” He invoked the Brady Bunch measles episode that anti-vaccine advocates cite as evidence the disease is benign, and recast it: “If that was actually a realistic depiction of measles, one of the Brady Bunch kids would have been in the hospital struggling to breathe.”

The HPV Dividend Wall Street Isn’t Pricing

The episode’s most encouraging data point sits in the cancer-prevention portfolio. A retrospective cohort study of 1.4 million individuals, published in the International Journal of Infectious Diseases, used propensity-score matching to compare 716,630 HPV-vaccinated individuals against an equal number of unvaccinated controls. The results: 40 head and neck cancers in the vaccinated group versus 130 in controls — a roughly 70% reduction, with more than 90% protection against oropharyngeal cancers specifically.

Griffin flagged the study as retrospective rather than a prospective randomized trial, but called the survival curves “really robust compelling” with “very no overlap.” The finding carries weight because when HPV vaccines were first developed, researchers did not yet know the virus caused oral cancers. The vaccine is now demonstrably a cancer-prevention tool, not merely an anti-infection measure.

This creates a quiet market inefficiency. While much of the oncology narrative in 2026 has centered on mRNA cancer vaccines from Moderna and BioNTech — with Moderna’s melanoma trial reading out positively and BioNTech’s colorectal trial collapsing — the HPV vaccine already delivers real-world cancer prevention at a fraction of the cost and regulatory risk. The population-level payoff from maintaining high HPV vaccination rates dwarfs the near-term revenue potential of many experimental oncology platforms. Yet because prevention has no blockbuster launch event, it is systematically undervalued by both policymakers and markets.

Food Safety as a Leading Indicator of Institutional Decay

The cyclospora numbers are the kind of data point that should trigger an emergency inquiry. Historically, the United States records roughly 1,000 cases of cyclosporiasis per year — a parasitic infection causing severe, prolonged diarrhea. Since May 2026, the CDC has logged 17,180 lab-confirmed cases, with an additional 11,844 reported. That is a roughly 30-fold increase in a preventable parasitic disease.

Griffin’s explanation is structural: reduced staffing and funding for imported food inspection. Even before the current administration, only about half of imported food was inspected. That figure has deteriorated further, and the pathogen load is showing up in human intestines. The same logic applies to a proposal to allow cattle imports from Mexico without adequate inspection — a move Griffin worries could introduce New World screwworm and other pathogens into the US livestock economy.

The implications for food producers, grocers, and restaurant chains are direct. A food-safety breakdown of this magnitude creates legal exposure, reputational risk, and potential demand shocks for categories dependent on imported fresh produce. More broadly, it signals that the institutional capacity to catch problems before they reach consumers is being deliberately degraded. For investors, that is a tail-risk expansion across the entire food supply chain.

Ebola in Congo: The Outbreak Outrunning Its Response

The current Ebola outbreak in the Democratic Republic of Congo, caused by the Bundibugyo virus, has recorded 5,584 cases and 2,680 confirmed deaths. The WHO has stated it is on track to surpass the 2014–2016 West African outbreak that killed over 11,000 people. The trajectory is worse than any previous outbreak: the current event is spreading faster, and less than 10% of cases are being traced to known contacts, meaning the contact-tracing infrastructure has effectively collapsed.

The Associated Press data cited in the episode suggests the true case count may be three times the reported figure — roughly 15,000 cases and potentially 7,000 deaths already.